HSIC Stock Analysis — Henry Schein
Sector: Healthcare Distribution
AI Verdict
Henry Schein trades at 14.3x next year's earnings with huge expected growth, making it cheap for the growth on offer if its sticky customer base and integrated platform keep competitors at bay.
Competitive Moat
Henry Schein is a dominant distributor of dental and medical supplies, leveraging long-term relationships with clinics and a vast logistics network to create high switching costs for customers. Its scale and integrated software offerings for practice management make it hard for smaller rivals to compete on both price and service.
Summary
A sharp drop in forward P/E to 14.3x with 82.5% expected EPS growth puts Henry Schein on value-watch as earnings are set to surge.
Where It Stands
Shares are up 17.49% over the past year, trade at 14.3x next year's earnings (well below the healthcare sector median of 22x), and the RSI at 69.0 signals elevated near-term pullback risk.
Key Metrics
- RSI: 69 — Near Overbought
- Trailing P/E: 26.1x
- Forward P/E: 14.3x
- PEG Ratio: 0.32
- Earnings Growth: +0.8%
- Revenue Growth: +0.1%
- Market Cap: $9.8B
- 1-Year Return: 17.49%
- 52-Week High: $89.29
- 52-Week Low: $61.95
Analyst Consensus
14 Buy · 9 Hold · 1 Sell (24 analysts)
Bull Case
With forward EPS growth forecast at 82.5% and a forward P/E of just 14.3x, you're paying a low price for a big earnings jump if the growth materializes.
Bear Case
An RSI of 69.0 means the stock is at elevated risk of a technical pullback, so a reversion to a 22x sector P/E would imply a sharp price drop if growth disappoints.
Catalyst to Watch
Watch for quarterly earnings — if the company delivers on the 82.5% EPS growth forecast, the low forward P/E could quickly re-rate upward.